News | Structural Heart | July 13, 2020

Edwards Lifesciences and Abbott Settle Transcatheter Mitral Valve Device Patent Litigation

Abbott will receive a one-time payment and ongoing payments in connection to Edward's Pascal device sales

A comparison of the Edwards Pascal (left) and the Abbott MitraClip used for transcatheter mitral and tricuspid valve leaflet repairs. The two companies settled patent litigation regarding the devices today.

July 13, 2020 — Edwards Lifesciences Corp. and Abbott Vascular announced the two companies have reached an agreement to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. 

The agreement will result in the dismissal of all pending cases or appeals in courts and patent offices worldwide, and includes a provision that the parties will not litigate patent disputes with each other in the field of transcatheter mitral and tricuspid repair and replacement products for the 10-year duration of the agreement. The injunctions currently in place against the sale of Edwards' transcatheter mitral and tricuspid repair system will be lifted.  

In connection with this agreement, Abbott will receive a one-time payment and ongoing payments based on the sales of the Edwards Pascal transcatheter valve repair system through 2025, as well as a potential sales milestone payment in 2026. The Pascal is very similar in design to the Abbott MitraClip device that is used for transcatheter mitral and tricuspid valve leaflet repairs.

Edwards said considers this agreement a positive development, as it allows the company to fully dedicate time and resources to helping patients.

Details of the settlement are confidential.

 

Related Transcatheter Mitral Valve Device Content:

Developments in Transcatheter Mitral Valve Replacement

Transcatheter Tricuspid Valve Repair Clip Device Cleared in Europe

New Study Looks at MitraClip use in Moderate Surgical Risk Patients

Edwards Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe

Edwards Announces Research Milestones for Pascal Transcatheter Mitral Valve Program
 

 


Related Content

News | Cardiovascular Business

January 24, 2023 — Cardiothoracic surgeon Thomas E. MacGillivray, MD, from MedStar Health, was elected President of The ...

Home January 24, 2023
Home
News | Cardiovascular Business

January 19, 2023 — The volunteers and staff of the American Heart Association and the American Stroke Association are ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 19, 2023 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 11, 2023 — The Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug ...

Home January 11, 2023
Home
News | Cardiovascular Business

January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under ...

Home January 09, 2023
Home
News | Cardiovascular Business

January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...

Home January 09, 2023
Home
News | Cardiovascular Business

January 5, 2023 — StreamlineMD has provided updates for 2023 Radiology and IR CPT coding, which may impact your practice ...

Home January 05, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

As 2022 comes to a close, the Diagnostic and Interventional Cardiology team takes a look at the year's most viewed ...

Home January 02, 2023
Home
News | Cardiovascular Business

December 27, 2022 — President Joe Biden signed into law the Cardiovascular Advances in Research and Opportunities Legacy ...

Home December 27, 2022
Home
News | Cardiovascular Business

December 22, 2022 — Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now ...

Home December 22, 2022
Home
Subscribe Now